Mirtazapine improves visual hallucinations in Parkinson's disease: A Case report

Psychogeriatrics

Volumn 13, Issue 2, 2013, Pages 103-107

  Tagai, Kenji ^a   Nagata, Tomoyuki ^a   Shinagawa, Shunichiro ^a   Tsuno, Norifumi ^a   Ozone, Motohiro ^a   Nakayama, Kazuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Lewy bodies; Mirtazapine; Parkinson's disease; Psychosis; Visual hallucinations

Indexed keywords

ARIPIPRAZOLE; CYSTEINE ETHYL ESTER TC 99M; MIRTAZAPINE; QUETIAPINE; RISPERIDONE; TRAZODONE; TRIHEXYPHENIDYL;

AGED; ARTICLE; BRADYKINESIA; BRAIN BLOOD FLOW; CASE REPORT; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEMENTIA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NURSING HOME; PARKINSON DISEASE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VISUAL HALLUCINATION;

LEWY BODIES; MIRTAZAPINE; PARKINSON'S DISEASE; PSYCHOSIS; VISUAL HALLUCINATIONS;

AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; FEMALE; HALLUCINATIONS; HUMANS; MIANSERIN; PARKINSON DISEASE; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 84879025257     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/j.1479-8301.2012.00432.x     Document Type: Article

References (32)

1. Bernard R, Karen M, Fernandez HH etal. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH Work Group. Mov Disord 2007; 22: 1061-1068.
2. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996; 53: 1265-1268.
3. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 533-535.
4. Fenelon G, Mahieux F, Huon R etal. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123 (Part 4): 733-745.
5. Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol 2005; 252: 753-764.
6. Eng ML, Welty TE. Management of hallucinations and psychosis in Parkinson's disease. Am J Geriatr Pharmacother 2010; 8: 316-330.
7. Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 311-313.
8. Voon V, Lang AE. Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. Clin Neuropharmacol 2004; 27: 90-92.
9. Dallas P, Nikesh A, Sudeep S etal. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011; (2)CD008191.
10. Fahn S, Elton R. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, eds. Recent Developments in Parkinson's Disease. New York: Macmillan, 1987; 153-163.
11. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
12. Dubois B, Slachevsky A, Litvan I etal. The FAB: a frontal assessment battery at bedside. Neurology 2000; 55: 1621-1626.
13. Reisberg B, Borenstein J, Salob SP etal. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 (Suppl.): 9-15.
14. Hamilton A. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
15. Zahodne LB, Fernandez HH. A review of the pathophysiology and treatment of psychosis in Parkinson's disease. Drugs Aging 2008; 25: 665-682.
16. Gilles F. Psychosis in Parkinson's disease: phenomenology, frequency, risk factors and current understanding of pathophysiologic mechanisms. CNS Spectr 2008; 13: 18-25.
17. Marsh L, Williams JR, Rocco M etal. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004; 63: 293-300.
18. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43: 2227-2229.
19. Carter JH, Stewart BJ, Archbold PG etal. Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study Group. Mov Disord 1998; 13: 20-28.
20. Friedman JH. Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat Disord 2010; 16: 553-560.
21. Rabey JM. Hallucinations and psychosis in Parkinson's disease. Parkinsonism Relat Disord 2009; 15S: S105-S110.
22. Emre M, Aarsland D, Albanese A etal. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518.
23. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003; 18: 937-941.
24. Mori S, Mori E, Iseki E etal. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open label study. Psychiatry Clin Neurosci 2006; 60: 190-195.
25. Lauterbach EC. Dopaminergic hallucinosis with fluoxetine in Parkinson's disease. Am J Psychiatry 1993; 150: 1750.
26. Normann C, Hesslinger B, Frauenknecht S etal. Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry 1997; 30: 263-265.
27. Zoldan J, Friedberg G, Goldberg-Stern H etal. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993; 341: 562-563.
28. Zoldan J, Friedberg G, Livneh M etal. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45: 1305-1308.
29. Ballanger B, Strafella AP, van Eimeren T etal. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010; 67: 416-421.
30. De Boer T. The pharmacological profile of mirtazapine. J Clin Psychiatry 1996; 57 (Suppl. 4): 19-25.
31. Witjas T, Kaphan E, Azulay JP etal. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408-413.
32. Seppi K, Weintraub D, Coelho M etal. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26: S42-S80.